ACTG A5201(V 20)-REGMIN SMPLFCTN TO ATAZANAVIR/RITONAVIR AFTR VRLGC SUPPRESSION

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 服用药物控制 HIV 感染的人通常会同时服用至少 3 种药物。例如，组合可能是 2 种核苷逆转录酶抑制剂 (NRTI) 和一种蛋白酶抑制剂。 有几项小型研究表明，使用蛋白酶抑制剂与少量利托那韦（Norvir）（另一种蛋白酶抑制剂）相结合，可以控制 HIV 感染，而无需使用其他 HIV 药物。这项研究的主要目的是观察服用蛋白酶抑制剂阿扎那韦 (Reyataz) 与少量利托那韦联合是否可以在不使用其他 HIV 药物的情况下控制 HIV 感染。这项研究还将了解这种疗法在治疗艾滋病毒感染方面是否安全，以及阿扎那韦与利托那韦一起使用时是否有任何副作用。 阿扎那韦和利托那韦经美国食品和药物管理局 (FDA) 批准与其他 HIV 药物一起用于治疗 HIV 感染。阿扎那韦联合利托那韦未获批准与其他 HIV 药物一起使用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. People taking medicines to control their HIV infection normally take at least 3 of these medicines at the same time. For example, a combination might be 2 nucleoside reverse transcriptase inhibitors (NRTI's) and a protease inhibitor. There are several small studies that suggest using a protease inhibitor combined with a low amount of ritonavir (Norvir), another protease inhibitor, can control HIV infection without using other HIV drugs. The main purpose of this research study is to see if taking atazanavir (Reyataz), a protease inhibitor, combined with a low amount of ritonavir will control HIV infection without using other HIV drugs. This study will also see if this treatment is safe in treating HIV infection and if there are any side effects when using atazanavir with ritonavir. Atazanavir and ritonavir are approved by the U.S. Food and Drug Administration (FDA) for use with other HIV drugs in the treatment of HIV infection. Atazanavir with ritonavir is not approved for use without other HIV drugs.